Collegium Pharmaceutical (NASDAQ:COLL) Reaches New 1-Year Low – What’s Next?

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $28.50 and last traded at $28.56, with a volume of 41338 shares changing hands. The stock had previously closed at $29.11.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on COLL shares. HC Wainwright lifted their price target on Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, September 5th. Piper Sandler reiterated a “neutral” rating and set a $37.00 target price on shares of Collegium Pharmaceutical in a research note on Friday, October 11th. Finally, StockNews.com downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $42.60.

Collegium Pharmaceutical Stock Down 1.6 %

The company has a market capitalization of $923.96 million, a PE ratio of 12.35 and a beta of 0.80. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. The stock’s 50 day moving average is $31.53 and its 200 day moving average is $34.20.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in COLL. Pacer Advisors Inc. boosted its position in shares of Collegium Pharmaceutical by 31.8% in the second quarter. Pacer Advisors Inc. now owns 3,408,369 shares of the specialty pharmaceutical company’s stock valued at $109,749,000 after acquiring an additional 821,541 shares during the period. Rubric Capital Management LP grew its position in shares of Collegium Pharmaceutical by 27.2% during the 2nd quarter. Rubric Capital Management LP now owns 2,333,500 shares of the specialty pharmaceutical company’s stock valued at $75,139,000 after purchasing an additional 499,473 shares in the last quarter. Principal Financial Group Inc. increased its holdings in shares of Collegium Pharmaceutical by 3.9% in the third quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company’s stock worth $67,459,000 after purchasing an additional 64,958 shares during the period. Renaissance Technologies LLC raised its position in shares of Collegium Pharmaceutical by 8.0% in the second quarter. Renaissance Technologies LLC now owns 1,531,498 shares of the specialty pharmaceutical company’s stock worth $49,314,000 after buying an additional 113,300 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Collegium Pharmaceutical by 2.0% during the second quarter. Dimensional Fund Advisors LP now owns 1,039,024 shares of the specialty pharmaceutical company’s stock valued at $33,457,000 after buying an additional 19,876 shares during the period.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.